JP2021073291A5 - - Google Patents

Download PDF

Info

Publication number
JP2021073291A5
JP2021073291A5 JP2021017236A JP2021017236A JP2021073291A5 JP 2021073291 A5 JP2021073291 A5 JP 2021073291A5 JP 2021017236 A JP2021017236 A JP 2021017236A JP 2021017236 A JP2021017236 A JP 2021017236A JP 2021073291 A5 JP2021073291 A5 JP 2021073291A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
conjugation
antibody
asgpr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021017236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021073291A (ja
JP7222004B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021073291A publication Critical patent/JP2021073291A/ja
Publication of JP2021073291A5 publication Critical patent/JP2021073291A5/ja
Priority to JP2023014370A priority Critical patent/JP7663616B2/ja
Application granted granted Critical
Publication of JP7222004B2 publication Critical patent/JP7222004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021017236A 2014-05-16 2021-02-05 自己免疫状態および炎症状態を治療するための方法および組成物 Active JP7222004B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023014370A JP7663616B2 (ja) 2014-05-16 2023-02-02 自己免疫状態および炎症状態を治療するための方法および組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461994239P 2014-05-16 2014-05-16
US61/994,239 2014-05-16
US201462014504P 2014-06-19 2014-06-19
US62/014,504 2014-06-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017512873A Division JP6836500B2 (ja) 2014-05-16 2015-05-15 自己免疫状態および炎症状態を治療するための方法および組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023014370A Division JP7663616B2 (ja) 2014-05-16 2023-02-02 自己免疫状態および炎症状態を治療するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2021073291A JP2021073291A (ja) 2021-05-13
JP2021073291A5 true JP2021073291A5 (enExample) 2021-10-28
JP7222004B2 JP7222004B2 (ja) 2023-02-14

Family

ID=54480787

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512873A Active JP6836500B2 (ja) 2014-05-16 2015-05-15 自己免疫状態および炎症状態を治療するための方法および組成物
JP2021017236A Active JP7222004B2 (ja) 2014-05-16 2021-02-05 自己免疫状態および炎症状態を治療するための方法および組成物
JP2023014370A Active JP7663616B2 (ja) 2014-05-16 2023-02-02 自己免疫状態および炎症状態を治療するための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017512873A Active JP6836500B2 (ja) 2014-05-16 2015-05-15 自己免疫状態および炎症状態を治療するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023014370A Active JP7663616B2 (ja) 2014-05-16 2023-02-02 自己免疫状態および炎症状態を治療するための方法および組成物

Country Status (8)

Country Link
US (2) US10993990B2 (enExample)
EP (1) EP3142691A4 (enExample)
JP (3) JP6836500B2 (enExample)
CN (1) CN106659774A (enExample)
AU (3) AU2015258875B2 (enExample)
CA (2) CA3185180A1 (enExample)
IL (2) IL300029A (enExample)
WO (1) WO2015175957A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
KR20240154672A (ko) 2014-02-21 2024-10-25 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR20200031571A (ko) * 2017-05-29 2020-03-24 가마맵스 파마 암 연관 면역억제의 억제제
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
SG11202011078VA (en) 2018-05-09 2020-12-30 Univ Chicago Compositions and methods concerning immune tolerance
CN119613548A (zh) * 2018-06-13 2025-03-14 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
CN109620952A (zh) * 2019-01-04 2019-04-16 北京中台恒基生物技术有限公司 一种肿瘤疫苗及其制备方法
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
JP7546924B2 (ja) * 2019-03-01 2024-09-09 国立大学法人 筑波大学 アレルギー疾患を処置することに用いるための組成物
CA3141327A1 (en) * 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
US12448440B2 (en) * 2019-08-23 2025-10-21 Loyota University Of Chicago Compositions comprising antibodies or antibody fragments which bind the P2X4 receptor
CN111544592B (zh) * 2020-03-13 2022-05-03 中山大学附属第一医院 模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用
EP4181957A4 (en) 2020-07-20 2024-08-07 Deka Biosciences, Inc. TWO-CYTOKINE FUSION PROTEIN COMPRISING IL-10
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
WO2022031870A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL27Rα BINDING MOLECULES AND METHODS OF USE
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
US12012457B1 (en) 2020-08-05 2024-06-18 Synthekine, Inc. IL23R binding molecules and methods of use
BR112023001723A2 (pt) 2020-08-05 2023-05-02 Synthekine Inc Moléculas de ligação à gp130 e métodos de uso
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
EP4192880A4 (en) 2020-08-05 2025-04-30 Synthekine, Inc. IL10 receptor-binding molecules and methods of use
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
CN116829585A (zh) 2020-08-05 2023-09-29 辛德凯因股份有限公司 Il27受体结合相关的组合物和方法
WO2022032025A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr binding synthetic cytokines and methods of use
JP7819178B2 (ja) 2020-08-05 2026-02-24 シンセカイン インコーポレイテッド ＩＬ１０Ｒｂ結合分子および使用方法
WO2022067334A1 (en) * 2020-09-25 2022-03-31 The University Of Chicago Anti-inflammatory cytokines and methods of use
CN112694532B (zh) * 2021-01-12 2023-04-18 倍而达药业（苏州）有限公司 抗Siglec-15的抗体或其抗原结合片段及应用
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
FR3139339B1 (fr) * 2022-09-01 2025-10-24 Asfalia Biologics Conjugués peptidiques et leur utilisation pour promouvoir l’immunotolérance aux nucleases cas dans une thérapie génique par ingenierie du genome
WO2024233853A2 (en) * 2023-05-11 2024-11-14 Elixiron Immunotherapeutics (hong Kong) Limited A combination comprising lag-3 targeting moiety and interleukin-10
WO2024249898A2 (en) * 2023-06-02 2024-12-05 Synthekine, Inc. Fused il10 polypeptides
WO2025049885A1 (en) * 2023-09-01 2025-03-06 The Regents Of The University Of Michigan Long-lived brain delivery of anti-inflammatory agents

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CA2159639A1 (en) 1993-04-02 1994-10-13 Vincent J. Miles Method for selective inactivation of viral replication
US20040258688A1 (en) 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
AU726108B2 (en) 1995-10-17 2000-11-02 Genencor International, Inc. Enzymatic array and process of making same
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
FR2748479A1 (fr) 1996-05-10 1997-11-14 Pasteur Institut Polypeptide comportant un nouveau domaine cohesine de type ii, composition enzymatique en comportant et fragments d'adn codant pour ces polypeptides
US6046158A (en) 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
BR9811675A (pt) 1997-07-09 2000-09-19 Schering Corp Genes isolados para proteìna da membrana de célula dentrìtica
US6777546B2 (en) 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US5945308A (en) 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
JP2000157282A (ja) 1998-11-30 2000-06-13 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
CA2365981A1 (en) 1999-03-24 2000-09-28 Board Of Regents, The University Of Texas System Linear and circular expression elements
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
AU778207B2 (en) 1999-04-21 2004-11-25 Basf Aktiengesellschaft Mixture of adipic or phthalic acid diesters and isomeric nonanols
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
AU784677B2 (en) 2000-03-02 2006-05-25 Abgenix, Inc. Human monoclonal antibodies against oxidized LDL receptor and pharmaceutical uses thereof
US20060222633A1 (en) * 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
FR2816060A1 (fr) 2000-10-27 2002-05-03 Pf Medicament Procede d'identification de nouvelles molecules se liant au recepteur lox et utilisation de ces molecules
AU2002332598A1 (en) 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
US20050106700A1 (en) 2001-10-11 2005-05-19 Tsuyoshi Nomura Method of purifying recombinant fused protein and method of producing protein using the same
WO2003036895A1 (en) 2001-10-25 2003-05-01 Renesas Technology Corp. Semiconductor integrated circuit for communication, modulating/demodulating device, and communication diagnosing method
AU2002363861A1 (en) 2001-11-30 2003-06-10 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an intigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
AU2003213640A1 (en) 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US6738985B2 (en) 2002-05-14 2004-05-25 David S. Hahn Disposable sweatband liner
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP2004236504A (ja) 2003-02-03 2004-08-26 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
EP1605974B1 (en) * 2003-03-04 2014-11-12 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US20050064509A1 (en) 2003-09-23 2005-03-24 The Regents Of The University Of California Use of templated self assembly to create novel multifunctional species
US20060019342A1 (en) 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7666596B2 (en) 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
US7592003B2 (en) 2005-09-30 2009-09-22 Oklahoma Medical Research Foundation Regulation of toll-like receptors on stem cells
GB0605735D0 (en) 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
KR20090008467A (ko) 2006-05-08 2009-01-21 필로겐 에스.피.에이. 치료용의 항체­표적 사이토카인
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
MX2009008140A (es) 2007-02-02 2009-10-26 Baylor Res Inst Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
NZ578657A (en) 2007-02-02 2012-02-24 Baylor Res Inst Multivariable antigens complexed with targeting humanized monoclonal antibody
EP2132226B1 (en) 2007-02-23 2019-03-27 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
CN101679949B (zh) 2007-02-23 2015-08-19 贝勒研究院 通过dectin-1激活人抗原呈递细胞的治疗性应用
FR2933816B1 (fr) * 2008-07-10 2015-08-21 Commissariat Energie Atomique Dispositif a coupleur selectif en longueur d'onde pour collection de la lumiere emise par une source laser.
EP3281955A1 (en) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
CA2813494A1 (en) * 2009-10-08 2011-04-14 President And Fellows Of Harvard College Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
CA2794499A1 (en) * 2010-04-01 2011-10-06 Immumomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
MX2012012833A (es) 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
RU2013110889A (ru) 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
AR083400A1 (es) * 2010-10-13 2013-02-21 Baylor Res Inst Direccionamiento de los antigenos a las celulas dendriticas humanas a traves del receptor de asialoglicoproteinas dc para producir celulas t reguladoras con il-10
US20120121592A1 (en) * 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
AU2011316777A1 (en) 2010-10-22 2013-06-13 University Of Florida Research Foundation, Inc. Antigen-specific, tolerance-inducing microparticles and uses thereof
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2012129227A1 (en) 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
TW201300418A (zh) 2011-03-25 2013-01-01 Baylor Res Inst 用於抗ｃ型肝炎病毒免疫之組合物及方法
AR086287A1 (es) 2011-05-05 2013-12-04 Baylor Res Inst Composicion inmunoestimulante, metodo
BR112015002085A2 (pt) 2012-08-08 2017-12-19 Roche Glycart Ag proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
US9771427B2 (en) * 2012-08-09 2017-09-26 Roche Glycart Ag ASGPR antibodies and uses thereof
CA2916694C (en) * 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis

Similar Documents

Publication Publication Date Title
JP7840836B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
US20220380445A1 (en) Serum albumin binders
CA2505325C (en) Stabilized single domain antibodies
EP1558645B1 (en) Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JP2023052839A5 (enExample)
EP4198055A1 (en) Antibody of il-11 and use thereof
JP2023519213A5 (enExample)
CN1638796A (zh) 施用抗TNFα抗体的方法
WO2022199590A1 (zh) 一种靶向bcma的纳米抗体及其应用
JP2019537617A5 (enExample)
WO2023116751A1 (zh) 抗人血管生成素3纳米抗体及其应用
WO2021082573A1 (zh) 抗il-4r单域抗体及其应用
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
WO2023279803A1 (zh) Rbv的蛋白结合分子及其用途
EP4294847A2 (en) Pancreas targeted therapeutics and uses thereof
WO2025223473A1 (zh) 抗gdf-15抗体及其应用
CA3005061C (en) Improved serum albumin-binding immunoglobulin variable domains
WO2025130748A1 (zh) 一种抗凝血因子XI/XIa抗体制剂
CN101443043A (zh) 抗体组合物和方法
TW202612728A (zh) 使用靶向表現her2之腫瘤之三特異性結合蛋白治療癌症之方法
WO2025174812A1 (en) Chimeric antigen receptor and/or synnotch receptor systems and cells and methods of their use
TW202241505A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法
MX2008006882A (en) Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1